CoChat
Sign Up
Cited by 286Inflammatory Biomarkers in Disease PrognosisAtherosclerosis and Cardiovascular DiseasesAcute Ischemic Stroke Management

Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality: Is It Time to Intervene?

Coller, Barry S.·2005·Arteriosclerosis, Thrombosis, and Vascular Biology
DOI 10.1161/01.atv.0000156877.94472.a5
Open this paper in CoChat — free account

Abstract

The association between leukocytosis and increased morbidity and mortality of ischemic vascular disease has been observed for more than half a century, and recent studies in >350,000 patients confirm the robustness of the association and the dramatically higher relative and absolute acute and chronic mortality rates in patients with high versus low leukocyte counts. Although there is reason to believe that the association is not causal (that is, that leukocytosis is simply a marker of inflammation), there is also reason to believe that the leukocytosis directly enhances acute thrombosis and chronic atherosclerosis. Leukocytosis also is associated with poor prognosis and vaso-occlusive events in patients with sickle cell disease, and experimental data suggest a direct role for leukocytes in microvascular obstruction. The only way to test whether leukocytes contribute directly to poor outcome in ischemic cardiovascular disease is to assess the effect of modifying leukocyte function or number. Because selective blockade of leukocyte integrin alphaMbeta2 and P-selectin have thus far been disappointing as therapeutic strategies in human cardiovascular and cerebrovascular disease, I discuss the potential risks and benefits of short-term treatment with hydroxyurea to decrease the leukocyte count in select populations of patients at the highest risk of short-term death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000156877.94472.a5

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 146 · Cited by 286

Part of this paper’s reference list could not be split into single entries.

Research works printed but not linked: 90

  1. Cole D, Singian E, Katz L. The long-term prognosis following myo- cardial infarction, and some factors which affect it. Circulation. 1954; 9:321-334.
  2. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc. 1998; 279:1477-1482.
  3. Cooper HA, Exner DV, Waclawiw MA, Domanski MJ. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol. 1999;84:252-257.
  4. Kammersgaard LP, Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Leukocytosis in acute stroke: relation to initial stroke severity, infarct size, and outcome: the Copenhagen Stroke Study. Journal of Stroke and Cerebrovascular Diseases. 1999;8:259 -263.
  5. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Asso- ciation between white blood cell count, epicardial blood flow, myo- cardial perfusion, and clinical outcomes in the setting of acute myo- cardial infarction: a Thrombolysis in Myocardial Infarction 10 substudy. Circulation. 2000;102:2329 -2334.
  6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary artery disease: prospective study and updated meta-analyses. BMJ. 2004;321: 199 -204.
  7. Kyne L, Hausdorff JM, Knight E, Dukas L, Azhar G, Wei JY. Neutro- philia and congestive heart failure after acute myocardial infarction. Am Heart J. 2000;139:94 -100.
  8. Barron HV, Harr SD, Radford MJ, Wang Y, Krumholz HM. The association between white blood cell count and acute myocardial infarction mortality in patients Ͼ or ϭ65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol. 2001;38: 1654 -1661.
  9. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Asso- ciation of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001;87:636 -639,A10.
  10. Hajj-Ali R, Zareba W, Ezzeddine R, Moss AJ. Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction. Am J Cardiol. 2001;88:1221-1224.
  11. Marchioli R, Avanzini F, Barzi F, Chieffo C, Di Castelnuovo A, Franzosi MG, Geraci E, Maggioni AP, Marfisi RM, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Valagussa F. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mor- tality risk chart. Eur Heart J. 2001;22:2085-2103.
  12. Noto D, Barbagallo CM, Cavera G, Cefalu' AB, Caimi G, Marino G, Lo CL, Caldarella R, Notarbartolo A, Averna MR. Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in southern Italy: an 8-year follow-up. Atherosclerosis. 2001; 157:225-231.
  13. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:901-908.
  14. Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, Mitamura H, Ogawa S. Prognostic significance of peripheral mono- cytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol. 2002;39:241-246.
  15. Albert AA, Beller CJ, Walter JA, Arnrich B, Rosendahl UP, Priss H, Ennker J. Preoperative high leukocyte count: a novel risk factor for stroke after cardiac surgery. Ann Thorac Surg. 2003;75:1550 -1557.
  16. Bagger JP, Zindrou D, Taylor KM. Leukocyte count: a risk factor for coronary artery bypass graft mortality. Am J Med. 2003;115:660 -663.
  17. Bhatt DL, Chew DP, Lincoff AM, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003;92:136 -140.
  18. Dacey LJ, DeSimone J, Braxton JH, Leavitt BJ, Lahey SJ, Klemperer JD, Westbrook BM, Olmstead EM, O'Connor GT. Preoperative white blood cell count and mortality and morbidity after coronary artery bypass grafting. Ann Thorac Surg. 2003;76:760 -764.
  19. Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart. 2003;89: 1200 -1204.
  20. Menon V, Lessard D, Yarzebski J, Furman MI, Gore JM, Goldberg RJ. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol. 2003;92:368 -372.
  21. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, Van de WF, White JA, Moliterno DJ, Topol EJ. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med. 2003;115:318 -321.
  22. Byrne CE, FitzGerald A, Cannon CP, Fitzgerald DJ, Shields DC. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Med Genet. 2004;5:13.
  23. Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, Hacke W. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke. 2004;35:1147-1152.
  24. Grzybowski M, Welch RD, Parsons L, Ndumele CE, Chen E, Zalenski R, Barron HV. The association between white blood cell count and acute myocardial infarction in-hospital mortality: findings from the National Registry of Myocardial Infarction. Acad Emerg Med. 2004;11: 1049 -1060.
  25. Tong PC, Lee KF, So WY, Ng MH, Chan WB, Lo MK, Chan NN, Chan JC. White blood cell count is associated with macro-and microvascular complications in chinese patients with type 2 diabetes. Diabetes Care. 2004;27:216 -222.
  26. Yarnell JW, Patterson CC, Sweetnam PM, Lowe GD. Haemostatic/ inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J. 2004;25: 1049 -1056.
  27. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
  28. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868 -874.
  29. Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, Lindgarde F. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Thromb Vasc Biol. 2004;24:1498 -1502.
  30. Grau AJ, Buggle F, Becher H, Zimmermann E, Spiel M, Fent T, Maiwald M, Werle E, Zorn M, Hengel H, Hacke W. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurology. 1998;50:196 -203.
  31. Ameriso SF, Wong VL, Quismorio FP Jr, Fisher M. Immunohema- tologic characteristics of infection-associated cerebral infarction. Stroke. 1991;22:1004 -1009.
  32. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vacci- nation. N Engl J Med. 2004;351:2611-2618.
  33. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25:85-89.
  34. Matsubara H. Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine therapy. Lancet. 2004;363:746 -747.
  35. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo LD, Sohn DW, Han KS, Oh BH, Lee MM, Park YB. Effects of intra- coronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004;363:751-756.
  36. Galimberti R, Pietropaolo N, Galimberti G, Kowalczuk A. Adult purpura fulminans associated with staphylococcal infection and admin- istration of colony-stimulating factors. Eur J Dermatol. 2003;13:95-97.
  37. Dereure O, Bessis D, Lavabre-Bertrand T, Exbrayat C, Fegueux N, Biron C, Guilhou JJ. Thrombotic and necrotizing panniculitis associated with recombinant human granulocyte colony-stimulating factor treatment. Br J Dermatol. 2000;142:834 -836.
  38. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO III. Outcomes and risks of granulocyte colony- stimulating factor in patients with coronary artery disease. J Am Coll Cardiol. In press.
  39. Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors-a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;75:368 -371.
  40. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004;10:171-178.
  41. Nakamura S, Imamura T, Okamoto K. Tissue factor in neutrophils: yes. J Thromb Haemost. 2004;2:214 -217.
  42. Palmerini T, Coller BS, Cervi V, Tomasi L, Marzocchi A, Marrozzini C, Leone O, Piccioli M, Branzi A. Monocyte-derived tissue factor con- tributes to stent thrombosis in an in vitro system. J Am Coll Cardiol. 2004;44:1570 -1577.
  43. Winkel P, Statland BE, Saunders AM, Osborn H, Kupperman H. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol. 1981;75:693-700.
  44. Thomson SP, Gibbons RJ, Smars PA, Suman VJ, Pierre RV, Santrach PJ, Jiang NS. Incremental value of the leukocyte differential and the rapid creatine kinase-MB isoenzyme for the early diagnosis of myo- cardial infarction. Ann Intern Med. 1995;122:335-341.
  45. Dale DC, Fauci AS, Guerry D, IV, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, pred- nisone, endotoxin, and etiocholanolone. J Clin Invest. 1975;56: 808 -813.
  46. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopu- lations of human lymphocytes. J Clin Invest. 1974;53:240 -246.
  47. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by pre- scription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764 -770.
  48. Nieto FJ, Szklo M, Folsom AR, Rock R, Mercuri M. Leukocyte count correlates in middle-aged adults: the Atherosclerosis Risk in Commu- nities (ARIC) Study. Am J Epidemiol. 1992;136:525-537.
  49. Cavalot F, Massucco P, Perna P, Traversa M, Anfossi G, Trovati M. White blood cell count is positively correlated with albumin excretion rate in subjects with type 2 diabetes. Diabetes Care. 2002;25: 2354 -2355.
  50. Woodman RJ, Watts GF, Puddey IB, Burke V, Mori TA, Hodgson JM, Beilin LJ. Leukocyte count and vascular function in type 2 diabetic subjects with treated hypertension. Atherosclerosis. 2002;163:175-181.
  51. Blair SN, Kohl HW, III, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. J Am Med Assoc. 1989;262: 2395-2401.
  52. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymp- tomatic North Am men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med. 1988;319:1379 -1384.
  53. Blair SN, Kampert JB, Kohl HW III, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. J Am Med Assoc. 1996;276:205-210.
  54. Church TS, Finley CE, Earnest CP, Kampert JB, Gibbons LW, Blair SN. Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome. Int J Obes Relat Metab Disord. 2002;26:805-813.
  55. Fisch IR, Freedman SH. Smoking, oral contraceptives, and obesity. Effects on white blood cell count. J Am Med Assoc. 1975;234:500 -506.
  56. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999; 150:341-353.
  57. Zhang Z, Chopp M, Zhang RL, Goussev A. A mouse model of embolic focal cerebral ischemia. J Cereb Blood Flow Metab. 1997;17: 1081-1088.
  58. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights from the Framingham Study. J Am Med Assoc. 1992;267:1253-1256.
  59. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Masoura C, Toutouzas P, Stefanadis C. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med. 2004;116: 145-150.
  60. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997; 96:1089 -1096.
  61. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med. 2002;30:S214 -S219.
  62. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neu- trophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reper- fusion injury. Circulation. 1989;80:1816 -1827.
  63. Thiagarajan RR, Winn RK, Harlan JM. The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thromb Haemost. 1997;78:310 -314.
  64. Martinez-Mier G, Toledo-Pereyra LH, Ward PA. Adhesion molecules and hemorrhagic shock. J Trauma. 2001;51:408 -415.
  65. Hartl R, Schurer L, Schmid-Schonbein GW, del Zoppo GJ. Experi- mental antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow Metab. 1996;16:1108 -1119.
  66. Heinel LA, Rubin S, Rosenwasser RH, Vasthare US, Tuma RF. Leu- kocyte involvement in cerebral infarct generation after ischemia and reperfusion. Brain Res Bull. 1994;34:137-141.
  67. Palatianos GM, Balentine G, Papadakis EG, Triantafillou CD, Vassili MI, Lidoriki A, Dinopoulos A, Astras GM. Neutrophil depletion reduces myocardial reperfusion morbidity. Ann Thorac Surg. 2004;77:956 -961.
  68. Vamvakas EC. Platelet transfusion and adverse outcomes. Lancet. 2004; 364:1736 -1738.
  69. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343-1360.
  70. Francis RB. Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses. 1991;35:88 -95.
  71. Steen RG, Xiong X, Langston JW, Helton KJ. Brain injury in children with sickle cell disease: prevalence and etiology. Ann Neurol. 2003;54: 564 -572.
  72. Olatunji PO, Davies SC. The predictive value of white cell count in assessing clinical severity of sickle cell anaemia in Afro-Caribbeans patients. Afr J Med Med Sci. 2000;29:27-30.
  73. Anyaegbu CC, Okpala IE, Akren'Ova YA, Salimonu LS. Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia (SCA). Eur J Haematol. 1998; 60:267-268.
  74. Okpala I. The intriguing contribution of white blood cells to sickle cell disease-a red cell disorder. Blood Rev. 2004;18:65-73.
  75. Pieters RC, Rojer RA, Saleh AW, Saleh AE, Duits AJ. Molgramostim to treat SS-sickle cell leg ulcers. Lancet. 1995;345:528.
  76. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351:959.
  77. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001;97:3313-3314.
  78. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound het- erozygous sickle cell/betaϩ thalassemia. Blood. 2001;97:3998 -3999.
  79. Okpala I, Daniel Y, Haynes R, Odoemene D, Goldman J. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol. 2002;69:135-144.
  80. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047-3051.
  81. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mor- tality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc. 2003;289:1645-1651.
  82. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039 -2045.
  83. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89:2319 -2327.
  84. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol. 2004;41:15-17.
  85. Fruchtman SM. Treatment paradigms in the management of myelopro- liferative disorders. Semin Hematol. 2004;41:18 -22.
  86. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95:3589 -3593.
  87. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloprolif- erative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003;74:26 -31.
  88. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med. 2000;133:925-926.
  89. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate athero- sclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61-67. 132. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. ␤3-integrin-deficient mice, but not P-selectin-deficient mice, develop intimal hyperplasia after vascular injury. Circulation. 2001;103: 2501-2507. 133. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation. 1997;96:4333-4342. 134.
  90. Akers DL, Lefer DJ, Chen IL, Wilkens RG, Rice J, Aurora H, Osgood TA, Bedi B, Tenaglia AN, Buda AJ, Kadowitz PJ, McNamara DB. Effect of short-term treatment with a monoclonal antibody to P-selectin on balloon catheter-induced: intimal hyperplasia, re-endothelialization, and attenuation of endothelial-dependent relaxation. Mol Cell Biochem. 1997;176:13-20. 135. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol. 2001;38:577-582. 136. Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Topol EJ, Lincoff AM, Wang K. Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscler Thromb Vasc Biol. 2002;22: 1598 -1603. 137. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES trig- gering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002;106: 1523-1529.

Authors
Coller, B. S.
Affiliations
Rockefeller University (US)
Corresponding author
Coller, Barry S.
ORCID
Coller, Barry S.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2005-04
Volume
25
Issue
4
Pages
658-670
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
DOI
10.1161/01.atv.0000156877.94472.a5
OpenAlex
W2164072021
Cited by
286
References
146
Citations by year
2026: 2 · 2025: 8 · 2024: 11 · 2023: 3 · 2022: 6 · 2021: 18 · 2020: 13 · 2019: 10 · 2018: 12 · 2017: 8 · 2016: 14 · 2015: 17 · 2014: 17 · 2013: 24 · 2012: 13
FWCI
7.85
Type
journal article
Language
en
Open access
closed
Locations
  • Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Public Health Service (54469, 19278)
  • National Heart, Lung, and Blood Institute (19278)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
Keywords
leukocytosis, ischemic vascular disease, cardiovascular mortality, thrombosis, atherosclerosis, sickle cell disease, vascular occlusion, P-selectin, hydroxyurea, leukocyte function, inflammation, cerebrovascular disease
MeSH terms
Humans, Ischemia, Leukocytosis, Morbidity, Prognosis, Vascular Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review